Compound class:
Synthetic organic
Comment: This compound is a particularly preferred example in patent US8664233 [1] which covers compounds for use in treating non-solid malignant hematological tumours, in particular, B cell leukemias.
|
|
No information available. |
Summary of Clinical Use |
The EMA granted this compound orphan drug designation in 2007, for the treatment of chronic lymphocytic leukemia (CLL). |